[1] Fang K, Yang Q, Lin Y, et al. Global cirrhosis prevalence trends and attributable risk factors-an ecological study using data from 1990-2019[J]. Liver Int, 2022, 42(12): 2791-2799.
[2] D'Amico G, Bernardi M, Angeli P. Towards a new definition of decompensated cirrhosis[J]. J Hepatol, 2022, 76(1): 202-207.
[3] Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial[J]. Lancet, 2018, 391(10138): 2417-2429.
[4] Caraceni P, Angeli P, Prati D, et al. AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis[J]. Blood Transfus, 2016, 14(1): 8-22.
[5] Caraceni P, Tufoni M, Zaccherini G, et al. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites[J]. J Hepatol, 2021, 74(2): 340-349.
[6] Wong F, Pappas S C, Curry M P, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome[J]. N Engl J Med, 2021, 384(9):818-828.
[7] Caraceni P, O'Brien A, Gines P. Long-term albumin treatment in patients with cirrhosis and ascites[J]. J Hepatol, 2022, 76(6): 1306-1317.
[8] Tufoni M, Baldassarre M, Zaccherini G, et al. Hemodynamic and systemic effects of albumin in patients with advanced liver disease[J]. Curr Hepatol Rep, 2020, 19(3): 147-158.
[9] Fernández J, Navasa M, Garcia-Pagan J C, et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis[J]. J Hepatol, 2004, 41(3): 384-390.
[10] Casulleras M, Flores-Costa R, Duran-Güell M, et al. Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis[J]. Science Translational Medicine, 2020, 12(566): eaax5135.
[11] Arroyo V, Angeli P, Moreau R, et al. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. J Hepatol, 2021,74(3):670-685.
[12] Garcia-Martinez R, Andreola F, Mehta G, et al. Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure[J]. J Hepatol, 2015, 62(4): 799-806.
[13] Fernández J, Clària J, Amorós A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis[J]. Gastroenterology, 2019, 157(1): 149-162.
[14] 单姗,赵连晖,马红, 等.肝硬化的定义、病因及流行病学[J].临床肝胆病杂志, 2021, 37(1):14-16.
[15] 卢爽,马明,陈雄.原发性肝癌术后患者生命意义感,死亡态度与生活质量的相关性研究[J].新疆医科大学学报, 2021, 44(8):975-980.
[16] Jalan R, D'Amico G, Trebicka J A, et al. New clinical and pathophysiological perspectives defining the trajectory of cirrhosis[J]. J Hepatol, 2021, 75(Suppl 1): S14-S26.
[17] Yeo Y H, He X, Lv F, et al. Trends of cirrhosis-related mortality in the USA during the COVID-19 pandemic[J]. J Clin Transl Hepatol, 2023, 11(3): 751-756.
[18] Balcar L, Semmler G, Pomej K, et al. Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure[J]. United European Gastroenterol J, 2021, 9(4): 427-437.
[19] 徐小元, 丁惠国, 李文刚, 等. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425.
[20] Wang Q, Zhao H, Deng Y, et al. Validation of Baveno Ⅶ criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77(6): 1564-1572.
[21] 欧阳生珀,童荣生.人血白蛋白的合理应用概述[J].中国医院药学杂志, 2021, 41(4):425-429.
[22] Rabbani G, Ahn S N. Structure, enzymatic activities, glycation and therapeutic potential of human serum albumin: a natural cargo[J]. Int J Biol Macromol, 2019,123:979-990.
[23] Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(12): 753-764.
[24] Zheng X, Bai Z, Wang T, et al. Human albumin infusion for the management of liver cirrhosis and its complications: an overview of major findings from meta-analyses[J]. Adv Ther, 2023, 40(4): 1494-1529.
[25] Bai Z, Méndez-Sánchez N, Romeiro F G, et al. Use of albumin infusion for cirrhosis-related complications: an international position statement[J]. JHEP Rep, 2023, 5(8): 100785.
[26] Zaccherini G, Baldassarre M, Tufoni M, et al. Correction and prevention of hyponatremia in patients with cirrhosis and ascites: post hoc analysis of the ANSWER study database[J]. Am J Gastroenterol, 2023, 118(1): 168-173.
[27] Iannone G,De Venutol C, Piano S, et al. Real-world experience of long-term albumin treatment in a large cohort of patients with cirrhosis and ascites (Real-ANSWER study)[C]. EASL, 2023.
[28] Laleman W, Trebicka J, Zaccherini G, et al. Real-world treatment of decompensated liver cirrhosis in Italy: a propensity score-matched analysis of long-term versus acute albumin therapy[C]. EASL, 2023.
[29] Xu X, Wang H, Zhao W, et al. Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study[J]. BMJ Open, 2021, 11(6): e043083.
[30] Hofer BS, Simbrunner B, Hartl L, et al. Hepatic recompensation according to Baveno Ⅶ criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis[J]. Liver Int, 2023, 43(10):2220-2231.
[31] Wen S, Ruan J, Shen J, et al. Development and validation of a nomogram to predict recompensation in HBV-related cirrhosis with ascites as the single first decompensating event [J]. Scand J Gastroenterol, 2023, 58(8): 915-922. |
